Archives
-
Cyclopamine Beyond the Product Page
2026-10-03
Cyclopamine is more than a Hedgehog signaling inhibitor for oncology models: it is a mechanistic probe for connecting Smoothened biology with developmental patterning, tumor-cell behavior, and translational biomarker strategy. This article interprets recent comparative penile-development findings while defining the evidence boundaries, competitive context, and future opportunities for Cyclopamine-centered research.
-
In Vitro Drug Response Metrics in Cancer Research
2026-10-02
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent components of an anticancer response. This framework helps researchers align assay endpoints, timing, and mechanistic interpretation more rigorously in preclinical cancer research.
-
BV6 IAP Antagonist: Workflow and Troubleshooting
2026-10-01
BV6 provides a practical way to test IAP-dependent survival, apoptosis induction in cancer cells, and radiosensitization of non-small cell lung cancer models. This guide connects dose planning, combination experiments, lysosomal death-pathway controls, and troubleshooting for more interpretable results.
-
FGFR3 Inhibition in SLC26A2 Chondrodysplasia
2026-10-01
The reference study combines genetic models, chondrocyte assays, and pharmacological intervention to show that excessive FGFR3 signaling contributes to SLC26A2-related skeletal dysplasia. Its findings link inhibition of downstream ERK1/2 and STAT1 signaling with improved chondrocyte behavior and bone microarchitecture, while defining important limits for translation beyond mice.
-
Oridonin, Inflammation, and Esophageal Cancer
2026-09-30
Peng et al. investigate whether oridonin suppresses experimental esophageal cancer by attenuating the TLR4/NF-κB/NLRP3 inflammatory axis. Their mouse study links improved tissue pathology and systemic inflammatory indices with changes in inflammasome-related proteins, proliferation markers, and apoptosis-associated transcripts, while also defining important limits for translation beyond the model.
-
ω-Agatoxin IVA Suppresses Seizures in Rats
2026-09-30
This rat study identifies selective P/Q-type (Cav2.1) calcium-channel blockade as a potential anticonvulsant and neuroprotective strategy. ω-Agatoxin IVA delayed seizure onset, reduced kindling and epileptic discharges, increased BDNF, and decreased cleaved caspase-3 without detectable motor-coordination impairment.
-
Prednisolone Workflows for Glucocorticoid Research
2026-09-29
Build reproducible Prednisolone assays for glucocorticoid receptor signaling, inflammation modulation, and corticosteroid-response profiling. A separate ERAD-focused section shows how the latest targeted degradation work can inform assay design without confusing receptor activation with transmembrane protein degradation.
-
GSK 2837808A: From LDHA to Tumor Immunity
2026-09-29
GSK 2837808A offers a focused way to interrogate LDHA-dependent lactate production while extending cancer metabolism research toward immune regulation. This article connects established hepatocellular carcinoma evidence with the NAT1–ENO1–lactate–PD-L1 mechanism reported in colorectal cancer, while clearly separating validated findings from hypothesis-generating translational strategies.
-
Lactate as a Causal Signal in Metabolic Research
2026-09-28
Lactate is both a glycolytic readout and an active regulator of redox, mitochondrial, hypoxia, and immune biology. This article develops a causal assay framework based on the NAT1–ENO1–lactate–TRAF6–PD-L1 pathway and explains how to distinguish metabolic association from mechanism.
-
Lovastatin Workflows for Mevalonate Research
2026-09-28
Use Lovastatin to probe HMG-CoA reductase activity across cholesterol metabolism, proliferation, apoptosis, and macrophage efferocytosis. This guide pairs model-specific dose planning with practical controls, while using a plant meristem study as a lesson in time-resolved experimental design—not as evidence of a direct plant–drug connection.
-
FGFR Inhibition Beyond Oncology: Lessons from NVP-BGJ398
2026-09-27
NVP-BGJ398 phosphate offers a way to test how FGFR1–3 signaling shapes biomarker-defined cancer models—and, with appropriate boundaries, to learn from emerging FGFR3 research in skeletal disease. This article connects target engagement to experimental design, translational interpretation, and the limits of cross-domain inference.
-
SU 5402 as a Pathway Probe in Human Neurons
2026-09-26
SU 5402 is a multi-target receptor tyrosine kinase inhibitor with established applications in cancer biology. This article examines how to use it cautiously as a pathway perturbation in human sensory-neuron studies, building on a human iPSC model of HSV-1 latency without implying that the compound was tested in that study.
-
KNUCKLES Coordinates Hormones to End Floral Meristems
2026-09-25
The study identifies KNUCKLES (KNU) as a regulator of floral meristem termination that links auxin distribution and cytokinin activity to chromatin-based repression of PIN1 and IPT7. Its findings extend the established KNU–WUS pathway and suggest that meristem determinacy depends on coordinating hormone patterns as well as stem-cell gene expression.
-
IDH2, α-KG, and HIF-1α in Colorectal Cancer
2026-09-25
This study links elevated IDH2 with reductive citrate-cycle metabolism, HIF-1α signaling, and colorectal cancer progression. By combining IDH2 inhibition with metabolic and tumor readouts, it identifies a metabolic dependency that may help guide mechanistic studies, while leaving the precise contribution of α-ketoglutarate to HIF regulation open for further testing.
-
LRPPRC Inhibition and Dasatinib Disrupt OXPHOS
2026-09-24
A high-throughput screen identified dasatinib as a candidate for combination with LRPPRC inhibition, revealing complementary suppression of nuclear- and mitochondrial-genome-encoded OXPHOS genes. The findings provide a mechanistic rationale for testing this dual-genome strategy in OXPHOS-dependent cancers, while leaving clinical efficacy and safety to be established.